Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kumar (Liverpool, United Kingdom), S. Zaidi (Liverpool, United Kingdom), N. Fay (Liverpool, United Kingdom), T. Fitzmaurice (Liverpool, United Kingdom), A. Watkin (Liverpool, United Kingdom), H. Joplin (Liverpool, United Kingdom), H. Burhan (Liverpool, United Kingdom). Efficacy of azithromycin in a real world severe asthma cohort. 1107

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Efficacy of azithromycin in severe asthma from the AMAZES randomised trial Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019 Year: 2019 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma Source: Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020 Year: 2021 Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Adherence to beclomethasone in children with persistent asthma in a low-income country: a randomized concurrent cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 162s Year: 2005 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Prevalence of oral corticosteroid use in the German severe asthma population Source: ERJ Open Res, 5 (4) 00092-2019; 10.1183/23120541.00092-2019 Year: 2019 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018